

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:	Völkel et al.	Docket No.:	52203
Serial No.:	10/076,514	Confirmation No.:	3431
Filing Date:	2/19/2002	Examiner:	YOUNG, MICAH PAUL
Customer No.:	26474	Art Unit:	1618

For: Crystalline choline ascorbate

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


INTERVIEW SUMMARY UNDER 37 C.F.R. § 1.133

Sir:

This is a summary of the telephone interview conducted on August 09, 2007.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees, to Deposit Account 14.1437. Please credit any excess fees to such account.

Respectfully submitted,
NOVAK DRUCE & QUIGG, LLP



Michael P. Byrne
Registration No.: 54,015

1300 Eye St. N.W.
Suite 1000 West
Washington, D.C. 20005
Phone: (202) 659-0100
Fax: (202) 659-0105

REMARKS

A telephonic interview took place on August 09, 2007, between Examiner Young, and Michael P. Byrne. To ensure a complete and proper recordation of the substance of the interview, applicants now submit the following applicable items:

(A) Identification of the claims discussed;

All of the pending claims, 6, 12, 13 and 23 – 25, were discussed.

(B) Identification of specific prior art discussed;

No prior art was discussed.

(C) Identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary form completed by the examiner;

Applicants' representative authorized the cancellation of claims 6, 12, and 13 in an examiner's amendment, so that claims 23 – 25 would be allowed to issue as a U.S. patent. Applicants intend to pursue claims 6, 12 and 13 in a Divisional application.

(D) The general thrust of the principal arguments of the applicant and the examiner

The examiner indicated that claims 23 – 25 would be allowed.

(E) A general indication of any other pertinent matters discussed;

No other pertinent matters were discussed.

(F) If appropriate, the general results or outcome of the interview; and

Claims 6, 12, and 13 will be cancelled and pursued in a Divisional Application. Claims 23 – 25 will be allowed to issue as a U.S. patent.